Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05909059 · ClinicalTrials.gov registry record · Phase 2
CAR T-cell Therapy in Patients With Renal Dysfunction
A Phase 2 study of Multiple Myeloma and Non-hodgkin Lymphoma,B Cell, sponsored by Northside Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05909059 is a Phase 2 study of Multiple Myeloma and Non-hodgkin Lymphoma,B Cell that is actively recruiting participants, run by Northside Hospital. The registered enrollment target is 20 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05909059, a Phase 2 study of Multiple Myeloma and Non-hodgkin Lymphoma,B Cell, is actively recruiting participants, sponsored by Northside Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
Study Locations (1)
Georgia
- Caitlin Guzowski - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2027-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05909059
The ClinicalTrials.gov registry entry for NCT05909059 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (96% lower). The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Cyclophosphamide is the first listed.
NCT05909059 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05909059 about?
NCT05909059 is a clinical study titled "CAR T-cell Therapy in Patients With Renal Dysfunction". This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.
What is the current status of trial NCT05909059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-11-18. Estimated completion is 2027-08-31.
What conditions does trial NCT05909059 study?
This clinical trial studies the following conditions: Multiple Myeloma, Non-hodgkin Lymphoma,B Cell, Acute Lymphoblastic Leukemia, Adult.
What interventions are being tested in trial NCT05909059?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG).
Who is sponsoring clinical trial NCT05909059?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05909059 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
-
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.